Tarsier Pharma Ltd.

Tarsier Pharma Ltd. has filed an amended F-1 registration statement for its initial public offering (IPO), aiming to raise capital for the development of its novel pharmaceutical therapies for blinding eye diseases. The company plans to offer 5,000,000 ordinary shares at an anticipated price range of $8.00 to $10.00 per share. Tarsier Pharma is developing TRS01 and TRS02, which target unmet needs in uveitis and uveitic glaucoma, and has secured a Special Protocol Assessment agreement with the FDA for its pivotal Phase 3 trial for TRS01. The company is leveraging its status as an emerging growth company and a foreign private issuer to utilize reduced disclosure requirements. A 10-for-1 forward stock split is planned before the offering closes.

Tarsier Pharma Ltd. filed an amendment to its F-1 registration statement, detailing plans for an initial public offering of 5,000,000 ordinary shares. The anticipated price range is $8.00 to $10.00 per share, with an assumed midpoint of $9.00. Prior to the offering, the company intends to effect a 10-for-1 forward stock split. Tarsier Pharma has applied to list its shares on the NYSE under "TARX" and has secured a Special Protocol Assessment (SPA) agreement with the FDA for its upcoming pivotal Phase 3 trial (Tarsier-04) for TRS01, with IOP safety as the primary endpoint.